FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046094097> ?p ?o ?g. }

• W2046094097 endingPage "440" @default.
• W2046094097 startingPage "431" @default.
• W2046094097 abstract "Cytolytic and helper T cells recognize small peptide fragments of protein antigens that are intracellularly processed and delivered to the cell surface in conjunction with HLA molecules. In mice, peptide vaccines can protect against lethal virus infections and tumor challenges. To test whether epitope peptides derived from a human tumor antigen can induce immune responses in patients, a vaccine was prepared consisting of an HLA-A1-restricted epitope of the antigen MAGE-3 mixed with a pan-class II epitope peptide PADRE and emulsified with incomplete Freund's adjuvant. Eighteen patients with resected stages III and IV melanoma at high risk for relapse were vaccinated subcutaneously with increasing doses of the MAGE-3 vaccine ranging from 100 to 2,000 micrograms per injection four times, each 4 weeks apart. The purpose of the phase I trial was to assess the toxicity, tolerability, and immune responses to the vaccine. The vaccine was not toxic, with only one case of grade III lethargy, and most patients complaining of grade I or II local pain, swelling, and tenderness at the injection sites. Peripheral blood mononuclear cells (PBMC) were collected from most patients prior to and after vaccination and used for assessment of global levels of immunity prevaccination, and to measure immune responses to the MAGE-3 and PADRE peptides prior to and after vaccination. Significant defects in global immunity shown by anergy to DTH skin testing in 7 of 16 patients and decreased proliferation to PHA (phytohemagglutinin) and CASTA, a Candida albicans protein extract, were observed. Seven of nine patients showed an increased response to PADRE after restimulation in vitro. Five of 14 patients at doses from 100 to 2,000 micrograms demonstrated an immune response to MAGE-3 by cytolysis of MAGE-3-specific target cells. Release of gamma interferon by T cells from 8 patients at the 100, 1,000, or 2,000 micrograms dose was measured after vaccination, and only two of eight patients showed an increase indicating augmented antigen-specific immunity. These data suggest that immune responses can be detected against PADRE and MAGE-3 in vaccinated melanoma patients, albeit with a low frequency of effector cells." @default.
• W2046094097 created "2016-06-24" @default.
• W2046094097 creator A5001879972 @default.
• W2046094097 creator A5032554768 @default.
• W2046094097 creator A5047177507 @default.
• W2046094097 creator A5059634145 @default.
• W2046094097 creator A5078613168 @default.
• W2046094097 creator A5086796342 @default.
• W2046094097 date "1999-09-01" @default.
• W2046094097 modified "2023-10-18" @default.
• W2046094097 title "A Phase I Trial of an HLA-A1 Restricted MAGE-3 Epitope Peptide with Incomplete Freundʼs Adjuvant in Patients with Resected High-Risk Melanoma" @default.
• W2046094097 doi "https://doi.org/10.1097/00002371-199909000-00007" @default.
• W2046094097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10546159" @default.
• W2046094097 hasPublicationYear "1999" @default.
• W2046094097 type Work @default.
• W2046094097 sameAs 2046094097 @default.
• W2046094097 citedByCount "118" @default.
• W2046094097 countsByYear W20460940972012 @default.
• W2046094097 countsByYear W20460940972013 @default.
• W2046094097 countsByYear W20460940972014 @default.
• W2046094097 countsByYear W20460940972015 @default.
• W2046094097 countsByYear W20460940972016 @default.
• W2046094097 countsByYear W20460940972017 @default.
• W2046094097 countsByYear W20460940972019 @default.
• W2046094097 countsByYear W20460940972020 @default.
• W2046094097 countsByYear W20460940972021 @default.
• W2046094097 countsByYear W20460940972022 @default.
• W2046094097 countsByYear W20460940972023 @default.
• W2046094097 crossrefType "journal-article" @default.
• W2046094097 hasAuthorship W2046094097A5001879972 @default.
• W2046094097 hasAuthorship W2046094097A5032554768 @default.
• W2046094097 hasAuthorship W2046094097A5047177507 @default.
• W2046094097 hasAuthorship W2046094097A5059634145 @default.
• W2046094097 hasAuthorship W2046094097A5078613168 @default.
• W2046094097 hasAuthorship W2046094097A5086796342 @default.
• W2046094097 hasConcept C126322002 @default.
• W2046094097 hasConcept C137061746 @default.
• W2046094097 hasConcept C147483822 @default.
• W2046094097 hasConcept C167672396 @default.
• W2046094097 hasConcept C188280979 @default.
• W2046094097 hasConcept C195616568 @default.
• W2046094097 hasConcept C197934379 @default.
• W2046094097 hasConcept C202751555 @default.
• W2046094097 hasConcept C203014093 @default.
• W2046094097 hasConcept C22070199 @default.
• W2046094097 hasConcept C2776789287 @default.
• W2046094097 hasConcept C2777863537 @default.
• W2046094097 hasConcept C2778375690 @default.
• W2046094097 hasConcept C2779053233 @default.
• W2046094097 hasConcept C2780868878 @default.
• W2046094097 hasConcept C55493867 @default.
• W2046094097 hasConcept C71924100 @default.
• W2046094097 hasConcept C86803240 @default.
• W2046094097 hasConcept C8891405 @default.
• W2046094097 hasConceptScore W2046094097C126322002 @default.
• W2046094097 hasConceptScore W2046094097C137061746 @default.
• W2046094097 hasConceptScore W2046094097C147483822 @default.
• W2046094097 hasConceptScore W2046094097C167672396 @default.
• W2046094097 hasConceptScore W2046094097C188280979 @default.
• W2046094097 hasConceptScore W2046094097C195616568 @default.
• W2046094097 hasConceptScore W2046094097C197934379 @default.
• W2046094097 hasConceptScore W2046094097C202751555 @default.
• W2046094097 hasConceptScore W2046094097C203014093 @default.
• W2046094097 hasConceptScore W2046094097C22070199 @default.
• W2046094097 hasConceptScore W2046094097C2776789287 @default.
• W2046094097 hasConceptScore W2046094097C2777863537 @default.
• W2046094097 hasConceptScore W2046094097C2778375690 @default.
• W2046094097 hasConceptScore W2046094097C2779053233 @default.
• W2046094097 hasConceptScore W2046094097C2780868878 @default.
• W2046094097 hasConceptScore W2046094097C55493867 @default.
• W2046094097 hasConceptScore W2046094097C71924100 @default.
• W2046094097 hasConceptScore W2046094097C86803240 @default.
• W2046094097 hasConceptScore W2046094097C8891405 @default.
• W2046094097 hasIssue "5" @default.
• W2046094097 hasLocation W20460940971 @default.
• W2046094097 hasLocation W20460940972 @default.
• W2046094097 hasOpenAccess W2046094097 @default.
• W2046094097 hasPrimaryLocation W20460940971 @default.
• W2046094097 hasRelatedWork W2073168426 @default.
• W2046094097 hasRelatedWork W2093686365 @default.
• W2046094097 hasRelatedWork W2152517822 @default.
• W2046094097 hasRelatedWork W2167073702 @default.
• W2046094097 hasRelatedWork W2217592602 @default.
• W2046094097 hasRelatedWork W2323045521 @default.
• W2046094097 hasRelatedWork W2356693239 @default.
• W2046094097 hasRelatedWork W2371751789 @default.
• W2046094097 hasRelatedWork W2586859946 @default.
• W2046094097 hasRelatedWork W4238291391 @default.
• W2046094097 hasVolume "22" @default.
• W2046094097 isParatext "false" @default.
• W2046094097 isRetracted "false" @default.
• W2046094097 magId "2046094097" @default.
• W2046094097 workType "article" @default.